Clinician-Guided Weight Management
Medical Weight Loss With GLP-1 Medications
GLP-1 receptor agonists and related medications can support chronic weight management for eligible patients when combined with nutrition, physical activity, and ongoing medical care. The right option depends on the approved indication, medical history, other medications, treatment goals, and availability.
A licensed clinician reviews contraindications, potential benefits, material risks, and product-specific instructions before prescribing. Results vary, and submitting an intake does not guarantee eligibility or a prescription.
Prescription treatment is subject to medical evaluation, product labeling, state availability, eligibility, and ongoing clinical monitoring.
Slide 1 of 3
Advanced Clinical Weight Loss Programs
These medications act on incretin pathways involved in appetite, food intake, glucose regulation, and gastric emptying. The summaries below describe trials of specific FDA-approved products used with lifestyle intervention; they do not establish equivalent results for compounded products or predict an individual result.
Semaglutide
Once-Weekly InjectionSemaglutide is a GLP-1 receptor agonist. Wegovy is FDA approved for chronic weight management in specific populations and has additional labeled indications. Dosing and eligibility must follow the selected product’s current prescribing information.
In adults without diabetes, semaglutide 2.4 mg weekly plus lifestyle intervention produced an estimated mean 14.9% body-weight reduction at 68 weeks versus 2.4% with placebo. Trial averages are not guarantees.
Tirzepatide
Once-Weekly InjectionTirzepatide is a dual GIP and GLP-1 receptor agonist. Zepbound is FDA approved for chronic weight management in specific populations. It can affect oral hormonal contraceptives after initiation and dose escalation; product-specific counseling is required.
In adults without diabetes, tirzepatide 15 mg plus lifestyle intervention produced a mean 20.9% body-weight reduction at 72 weeks versus 3.1% with placebo. Trial averages are not guarantees.
Liraglutide
Once-Daily InjectionLiraglutide is a daily GLP-1 receptor agonist. Saxenda is FDA approved for chronic weight management in specific populations. Whether a daily option is appropriate depends on the patient and current product labeling.
In adults without diabetes, liraglutide 3.0 mg plus lifestyle intervention produced a mean 8.0% body-weight reduction at 56 weeks versus 2.6% with placebo. Trial averages are not guarantees.
What Are GLP-1 Medications?
TRT National provides clinician-led telemedicine evaluation for adults seeking medical weight-management care where services are available. Eligibility, medication selection, treatment, and results are individualized, and availability varies by state. Submitting an intake does not guarantee treatment or a prescription.
Semaglutide and liraglutide are GLP-1 receptor agonists. Tirzepatide activates both GIP and GLP-1 receptors. These medicines act on pathways involved in appetite, food intake, glucose regulation, and gastric emptying, and are used with nutrition, physical activity, and clinical follow-up. This page reviews semaglutide, tirzepatide, and liraglutide; the appropriate option depends on the patient, indication, product, and prescriber.
Semaglutide: Once-Weekly GLP-1 Therapy
Semaglutide is a GLP-1 receptor agonist. An FDA-approved semaglutide product is indicated for chronic weight management in eligible patients when used with a reduced-calorie diet and increased physical activity.
Key Benefits
- Weight management: Clinical trials found meaningful average body-weight reduction in eligible adults when treatment was combined with lifestyle intervention.
- Cardiovascular context: FDA-approved Wegovy has a population-specific indication to reduce major cardiovascular-event risk in certain adults with established cardiovascular disease and overweight or obesity. This indication should not be generalized to every patient or product.
- Glycemic effects: GLP-1 receptor activation can improve glycemic measures. Hypoglycemia risk depends on diabetes status and concomitant medicines.
Science & Research
In STEP 1, adults without diabetes who received semaglutide 2.4 mg plus lifestyle intervention had a mean body-weight change of -14.9% at 68 weeks, compared with -2.4% with placebo. In SELECT, semaglutide 2.4 mg reduced major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. These trial results are product- and population-specific, do not predict an individual result, and should not be attributed to compounded semaglutide.
Dosing & Administration
Frequency and schedule: FDA-approved Wegovy injection is administered once weekly on the same day, at any time of day, with or without meals.
Label example: Wegovy injection is labeled to begin at 0.25 mg weekly for the first four weeks, followed by stepwise escalation at four-week intervals. The actual product, dose, escalation schedule, and maintenance dose must be selected by the prescriber according to indication and tolerability. Compounded concentrations and instructions can differ.
Side Effects & Safety
Common adverse effects include nausea, diarrhea, vomiting, constipation, and abdominal discomfort. Some gastrointestinal effects may decrease over time, but persistent or severe symptoms require clinician review. Important warnings and contraindications include thyroid C-cell tumor risk, pancreatitis, gallbladder disease, kidney injury related to dehydration, severe gastrointestinal reactions, hypersensitivity, and increased hypoglycemia risk with some diabetes medicines. This is not a complete risk list; review the current prescribing information with a clinician.
Tirzepatide: Dual GIP and GLP-1 Therapy
Tirzepatide activates both GIP and GLP-1 receptors and is administered once weekly. An FDA-approved tirzepatide product is indicated for chronic weight management in eligible patients alongside diet and physical activity.
Key Benefits
- Dual-pathway activity: GIP and GLP-1 receptor activation affects appetite, food intake, and glucose regulation.
- Weight management: Clinical trials found substantial average body-weight reduction, with outcomes differing by dose, tolerability, adherence, and patient factors. Body-weight results should not be described as guaranteed body-fat loss.
- Metabolic measures: Trial participants also experienced changes in measures such as waist circumference, blood pressure, lipids, and glycemia. Individual effects vary and require monitoring.
Science & Research
In SURMOUNT-1, adults without diabetes had mean body-weight changes at 72 weeks of -15.0%, -19.5%, and -20.9% with weekly 5 mg, 10 mg, and 15 mg tirzepatide, respectively, compared with -3.1% with placebo. Participants also received lifestyle intervention. These are group averages, not guaranteed outcomes.
Dosing & Administration
Frequency: FDA-approved Zepbound is administered once weekly.
Label example: Zepbound is labeled to begin at 2.5 mg weekly for four weeks. Subsequent increases occur in 2.5 mg increments only after at least four weeks at the current dose, according to treatment response and tolerability. The introductory 2.5 mg dose is not a maintenance dose. A prescriber must direct every dose change or switch.
Side Effects & Safety
Common adverse effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, and injection-site reactions. Important warnings and contraindications include thyroid C-cell tumor risk, pancreatitis, gallbladder disease, kidney injury related to dehydration, severe gastrointestinal reactions, hypersensitivity, and hypoglycemia with certain diabetes medicines. Tirzepatide also requires product-specific counseling about oral hormonal contraceptives after initiation and dose escalation. This is not a complete risk list.
Liraglutide: Once-Daily GLP-1 Therapy
Liraglutide is a once-daily GLP-1 receptor agonist. A prescriber may delay dose escalation or discontinue treatment when tolerability or response warrants; the daily schedule does not guarantee easier or safer adjustment.
Key Benefits
- Daily schedule: Treatment is administered once daily and adjusted gradually according to current product labeling and tolerability.
- Appetite management: GLP-1 receptor activation can increase fullness and reduce food intake.
- Clinical evidence: Liraglutide has been studied in multiple metabolic and weight-management trials. Its clinical history does not predict suitability or safety for an individual patient.
Science & Research
In the 56-week SCALE Obesity and Prediabetes trial, adults receiving liraglutide 3.0 mg plus lifestyle intervention lost a mean 8.4 kg, compared with 2.8 kg with placebo. Individual response varies.
Dosing & Administration
Frequency: FDA-approved Saxenda is administered once daily.
Label example: Saxenda is labeled to begin at 0.6 mg daily for week 1, then increase weekly through 1.2 mg, 1.8 mg, 2.4 mg, and the adult maintenance dose of 3.0 mg. A clinician determines whether escalation should be delayed or treatment discontinued because of tolerability or response.
Side Effects & Safety
Common adverse effects include nausea, diarrhea, constipation, vomiting, headache, and injection-site reactions. Hypoglycemia risk is higher with insulin or an insulin secretagogue. Important warnings and contraindications include thyroid C-cell tumor risk, pancreatitis, gallbladder disease, kidney injury related to dehydration, severe gastrointestinal reactions, and hypersensitivity. Injection sites should be rotated as directed. This is not a complete risk list.
Safety, Side Effects, and Contraindications
GLP-1 and related medications can cause common and serious adverse effects. Risk differs by product, dose, medical history, and other medications. This summary is not a substitute for the current prescribing information or clinician counseling.
Common and Serious Risks
Nausea, vomiting, diarrhea, constipation, and abdominal pain are common. Patients should also be counseled about product-specific warnings and when to seek urgent care:
- Pancreatitis and gallbladder disease
- Acute kidney injury related to dehydration or volume depletion
- Severe gastrointestinal reactions; some products are not recommended in severe gastroparesis
- Hypoglycemia risk when combined with insulin or insulin secretagogues
- Serious hypersensitivity reactions
- Delayed gastric emptying and aspiration risk during anesthesia or deep sedation
- Fetal harm; pregnancy planning requires product-specific guidance
Clinical Contraindications
Current labels for semaglutide, tirzepatide, and liraglutide include important contraindications and warnings. A prescriber must review at least:
- A personal or family history of Medullary Thyroid Carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Prior serious hypersensitivity to the selected product or an ingredient.
- Pregnancy, planned pregnancy, or breastfeeding considerations.
- History of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney disease, diabetic retinopathy, and interacting diabetes medications.
- All current medications, upcoming procedures requiring anesthesia, and use of oral hormonal contraceptives when tirzepatide is considered.
A licensed clinician must review your medical history, current medications, pregnancy plans, and individual risk factors. Seek urgent medical care for severe or concerning symptoms.
FDA-Approved and Compounded Medications Are Not Equivalent
Compounded medications are not FDA approved. FDA does not review them for safety, effectiveness, or quality before marketing. They should not be described as the same as an approved product or as a clinically proven substitute.
A clinician may consider a compounded medication only when an individual patient’s medical need cannot be met by an available FDA-approved drug, subject to applicable federal and state law. Product identity, pharmacy, concentration, and instructions must be clearly disclosed.
Important treatment principles include:
Product-Specific Instructions
Dose initiation, escalation, missed-dose guidance, stopping, and switching must follow the selected product’s current label and the prescriber’s instructions. There is no universal switching schedule.
Long-Term Planning
Obesity is a chronic condition. Ongoing treatment duration is individualized, and substantial weight regain can occur after medication withdrawal.
Protecting Overall Health
Weight loss can include both fat and lean mass. Adequate nutrition, resistance activity when appropriate, and clinical monitoring support health, but no TRT combination has been proven to guarantee lean-mass preservation or cardiovascular protection.
GLP-1 Treatment and Clinically Confirmed Low Testosterone
Some adults seeking weight-management care also report symptoms that can occur with low testosterone. Obesity and hypogonadism require separate clinical evaluations. TRT is not a routine add-on to GLP-1 therapy and should not be prescribed solely to accelerate weight or fat loss. It may be considered only when compatible symptoms or signs and consistently low testosterone are confirmed, followed by evaluation of the cause, fertility goals, contraindications, benefits, and risks.
Direct evidence proving added weight-management benefit from combining GLP-1 medication with TRT is limited. If both treatments are clinically indicated, decisions and monitoring are individualized.
Weight-management evaluation + hypogonadism evaluation = individualized care when both diagnoses are confirmed.
- Lean mass: Weight loss can include fat-free mass. Adequate nutrition, resistance exercise when appropriate, and monitoring of strength and body composition remain foundational. TRT does not guarantee that GLP-1-associated weight loss will come almost exclusively from fat.
- Weight and metabolic goals: TRT is not a weight-loss medication and should not be presented as an accelerator of GLP-1-related fat loss. Treatment goals and response are individualized.
- Energy and sexual symptoms: Adults with confirmed hypogonadism may discuss potential symptom benefits. Fatigue, concentration changes, mood changes, and low libido have many possible causes.
- Cardiovascular and endocrine safety: Combining TRT and GLP-1 treatment has not been proven to create comprehensive cardiovascular or endocrine protection. Each therapy requires a separate indication, contraindication review, and monitoring plan, including blood-pressure monitoring when testosterone is prescribed.
The TRT National Telemedicine Journey
Care begins online where telehealth services are available. Eligibility, laboratory needs, medication choice, pharmacy fulfillment, shipping, and timing depend on the individual evaluation, applicable law, and availability.
Digital Intake
Share your medical history, current medications, symptoms, prior treatment, and goals through the secure intake. Submitting an intake does not guarantee treatment or a prescription.
Blood Work & Consultation, When Indicated
A licensed clinician reviews the intake and determines whether laboratory testing, records, or another evaluation is needed. When appropriate and available in the patient’s state, a virtual consultation is used to discuss options, risks, and next steps.
Discreet Home Delivery
If treatment is prescribed, the patient receives product-specific directions and follow-up requirements. Medication may be dispensed and shipped by an appropriately licensed pharmacy where permitted. Product availability, pharmacy selection, shipping eligibility, and delivery times vary.
Frequently Asked Questions
Can I transition from semaglutide to tirzepatide if my weight-loss progress stalls?
A clinician may consider a change for some patients, but a new review is required and there is no universal dose conversion. Timing and starting dose depend on the products, medical history, response, and tolerability. Do not overlap products, reuse a prior dose, or change timing without individualized prescriber instructions.
Are these legally compounded prescriptions or research chemicals?
TRT National does not offer products labeled for research use as human treatment. Compounded drugs are not FDA approved, and FDA does not review them for safety, effectiveness, or quality before marketing. A compounded medication may be considered only when a licensed clinician identifies a patient-specific medical need that an available FDA-approved medicine cannot meet and applicable requirements are satisfied. If appropriate, a prescription may be sent to an appropriately licensed pharmacy. Availability is not guaranteed.
Do I have to stay on a GLP-1 medication forever?
Obesity is a chronic condition, and treatment duration is individualized. Some patients continue medication long term; others change or stop after clinician review. Weight regain can occur after discontinuation, so any transition plan should include follow-up, nutrition, physical activity, and appropriate alternatives. Do not stop or restart medication without prescriber guidance.
Start With a Medical Evaluation
Complete the secure intake, review your history and goals with a licensed clinician, and receive an individualized recommendation. If treatment is appropriate, the clinician explains the selected product, dosing, risks, alternatives, and follow-up plan.
Availability, eligibility, pharmacy fulfillment, and medication shipping vary by state. No specific medication, prescription, or result is guaranteed.
Individual results vary. Compounded medications are not FDA approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.